Platform
Features
Morphic Therapeutic
Contact
Gustav Christensen was President and CEO of Dyax Corp (NASDAQ: DYAX) from January 1, 2009 till it was acquired by Shire for $6.5 billion in January 2016. He joined Dyax early 2007 as EVP and Chief Business Officer.
14 members
Catalyst Pharmaceuticals
Nemaura Pharma
Nitin Lifesciences Ltd.
Catalent
Boehringer Ingelheim